Immune-related adverse events associated with immune-checkpoint inhibitors therapy in Mexican patients: Experience at a single center

Autor: Gabriela Juárez Salazar, María de Jesús Gonzalez Blanco, José Carlos Arroyo Kuribreña, Alfredo Domínguez Peregrina, Juan Carlos García Reyna, José Manuel Aguilar Priego, Enrique Miguel Cruz, Iván Romarico Romarico Gonzalez Espinoza, Julio Cesar Garibay Diaz, Giovanni Tobón Helú, Neil Cortés Escobar, Mónica Sabaté Fernández, Rebeca Ibarra Fernández, Carlos Cordero Vargas, Mariana Chiquillo-Domínguez, Eric Acosta Ponce de León, Feliciano de Jesús Vizcarra Ramos, Anna Gozalishvili Boncheva, Carmen Aguilar, Sergio Sánchez Sosa
Rok vydání: 2021
Předmět:
Zdroj: Journal of Clinical Oncology. 39:e14580-e14580
ISSN: 1527-7755
0732-183X
DOI: 10.1200/jco.2021.39.15_suppl.e14580
Popis: e14580 Background: The use of immune-checkpoint inhibitors (ICIs) for solid malignancies is rapidly rising, and many new agents and treatment combinations are in development. However, ICIs have a unique side-effect profile of immune-related adverse events (irAEs) compared with chemotherapeutic agents or targeted therapies. The aim of this work was to describe the irAEs in diverse types of malignant tumors using real-world data. Methods: This is a retrospective and descriptive study of patients with diverse types of advanced malignancies treated with immunotherapy at Centro Oncológico Integral of the Hospital Ángeles in Puebla, México; during the period 2016-2020. Data about the primary neoplasm, ICIs, irAEs, organ system affected, grade and treatment was collected. Clinical and laboratory parameters were obtained by reviewing medical records. Results: A total of 117 patients were included, median age of 65 years, of which 63.2% were male and 36.8% were female. The most frequent neoplasms treated with ICIs were: lung (27.4%), kidney (16.2%), melanoma (12.8%), hepatocellular (9.4%), breast (8.5%), non-melanoma skin cancer (6.0%), mesothelioma (4.3%) and other tumors (15.3%). 39.3% of the patients had no metastases, 41.9% had metastases to at least 1 or 2 sites, and 18.8% to 3 or more sites. The types of ICIs were: nivolumab (35.0%), pembrolizumab (28.2%), atezolizumab (23.9%), ipilimumab + nivolumab (12.0%) and durvalumab (0.9%). The most frequent irAEs were: gastrointestinal (61.5%), neurologic (46.2%), pulmonary (38.5%), metabolic (32.5%) and hematologic (29.1%). 39.3% of the irAEs were reported as grade 1, 31.6% as grade 2, 14.5% as grade 3 and 2.6% as grade 4. Conclusions: Our work shows the incidence of irAEs in a poorly studied population and provides new data that complement that reported by other works, however, further prospective studies are necessary.[Table: see text]
Databáze: OpenAIRE
Externí odkaz: